Startups

MELTIN MMI Predecessor

Tokyo, Japan

Closed historical 株式会社メルティンMMI, corporate number 7012401024371, founded July 19, 2013. Raised the 2018 Series B; do not attribute that round to the 2024 corporation with the same name. MELTz business transferred to FrontAct in June 2024.

Founded 2013

Team

No team members on record yet.

Investments

¥2.02B2018-10-17

Sumitomo Pharma, SBI Investment, Dai-ichi Life Insurance Company, Limited

team@apexlogos.ai21 hours ago
RELATED
team@apexlogos.ai21 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: MELTINMMIPredecessor. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # MELTIN MMI Reviewed 2026-10-06. Proposed ID `MeltinMMI` requires legal-entity review. Research only. ## Identity and import decision **Real business/brand, but hold corporate funding/team import pending predecessor-successor separation.** Official site [meltin.jp](https://www.meltin.jp/); Japanese name 株式会社メルティンMMI. Current [company profile](https://www.meltin.jp/about/) lists **August 8, 2024 incorporation**, Tokyo address Nihonbashi Kabutocho 17-2, Chuo-ku, Hayama Building 4F. Historical [2018 financing release](https://www.meltin.jp/en/news/293/) identifies a company founded **July 19, 2013** at a different Tokyo address. Crucially, the predecessor with corporate number **7012401024371** is marked **closed** by [Japan government gBizINFO](https://info.gbiz.go.jp/hojin/ichiran?hojinBango=7012401024371). A [newer same-name company is independently listed by gBizINFO](https://info.gbiz.go.jp/hojin/ichiran?hojinBango=2010001247406) under corporate number **2010001247406**, consistent with the current profile. Its legal identity is therefore supported by a government source; asset succession and historical-investor continuity still require review. The ministry's [J-Startup listing](https://www.j-startup.go.jp/startups/207-meltin.html) still identifies the old corporate number. No MELTIN name match found in read-only adex `Org` search. Do not import a single uninterrupted 2013-to-present entity with current funding claims by assumption. ## Audit of pasted entry | Claim | Assessment | |---|---| | Tokyo, Japan | Confirmed for current business address. | | $20M total | Unverified and potentially attached to closed predecessor. 2018 Series B alone was JPY 2.02B, translated by company to USD 17.7M. | | MELTz product | **Stale ownership.** MELTz business transferred to FrontAct, wholly owned by Sumitomo Pharma, on June 17, 2024. | | Active | Website/brand is live; predecessor legal corporation is closed. Must qualify status by legal entity. | | CEO blank | Site lists Masahiro Kasuya as CEO/CTO, but broader inherited team cards need currency checks. | [Official transfer announcement](https://www.meltin.jp/news/1338/), [product page confirming completed transfer](https://www.meltin.jp/products/medical/meltz/). MELTz uses muscle signals and AI for hand rehabilitation; do not treat it as an implanted brain-reading device. Current site describes robotics/body-augmentation work. ## Images and publicly listed team Official company profile artwork from `og:image`: [direct PNG](https://www.meltin.jp/cms/wp-content/uploads/2018/03/ogp_top.png), source [About HTML](https://www.meltin.jp/about/). These identified portraits remain published as CSS background images; publication alone does not prove current employment in the new corporation. | Person | Role / status | Profile / evidence | Direct pfp URL | |---|---|---|---| | 粕谷昌宏 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](//www.meltin.jp/cms/wp-content/themes/meltin/assets/images/about/visual-top.jpg) | | 市橋徹 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2023/04/ec55288a0103d7e1022b5c8c4a5db01a-scaled.jpg) | | 北林綾子 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2023/04/27d0e20e5b8490e8c5ea62b77dc8e9d8-1-scaled.jpg) | | 畑崎計成 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2023/07/f20f734b6b3a0322b98c6ad9ca880cbe-scaled.jpg) | | 西中重行 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/12/nishinaka.jpg) | | 小正瑞季 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/03/komasa.jpg) | | 内田毅彦 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/03/uchida-1.jpg) | | 伊藤寿美夫 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/03/ito.jpg) | | 深町周輔 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/12/fukamachi.jpg) | | 田崎佑樹 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/03/tazaki.jpg) | | 篠田正博 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/03/shinoda.jpg) | | 山本健策 | Public team card; legacy status to verify | [Profile](https://www.meltin.jp/about/) | [Photo](https://www.meltin.jp/cms/wp-content/uploads/2018/03/yamamoto.jpg) | Public roles on the page: Masahiro Kasuya (粕谷昌宏), CEO/CTO; Toru Ichihashi (市橋徹), COO/CFO; Ayako Kitabayashi (北林綾子), medical-business head; 計成畑崎, medical engineering head (romanization not independently established); Shigeyuki Nishinaka, director; Mizuki Komasa, director; Takahiro Uchida, advisor; 寿美夫伊藤, director; Shusuke Fukamachi, auditor. Confirm preferred romanizations and current company affiliations before Person import. ## Historical investments (predecessor) | Date | Amount | Type | Named participants | Evidence | |---|---:|---|---|---| | 2018-10-17 | JPY 2.02B; company English release USD 17.7M equivalent | Series B / third-party share allocation | Sumitomo Dainippon Pharma (now Sumitomo Pharma); SBI Investment; Dai-ichi Life Insurance. Lead not specified. | [Japanese company release](https://www.meltin.jp/news/279/), [English release](https://www.meltin.jp/en/news/293/) | Amounts describe one round, **not two rounds in two currencies**. Current 2024 corporation funding remains unknown. Earlier/follow-on rounds and comprehensive total are not verified here. ## Asset transaction, separate from financing MELTz manufacturing/sales/development business transfer: agreement April 16, 2024; completed June 17, 2024; buyer **FrontAct** (100% Sumitomo Pharma subsidiary); consideration **undisclosed**. [Official announcement](https://www.meltin.jp/news/1338/), [completed transfer confirmation](https://www.meltin.jp/products/medical/meltz/). This is a business sale, not an equity financing or acquisition of all MELTIN. No verified debt/grant amount was found. ## Review caveats Prioritized entity discontinuity, current product ownership and funding attribution. New corporation cannot inherit old investor relationships without evidence. The published 2023 leadership cards may survive from predecessor; treat them as research leads, not a clean current team. Hold those relations for review.